ArticleAnnals of nuclear medicine2026
Predictive value of left ventricular
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnthracycline-induced cardiotoxicity significantly impacts the survival and quality of life of lymphoma patients. Since traditional echocardiographic markers often detect injury only after irreversible damage, there is an urgent need for early biomarkers. We aimed to evaluate the predictive value of myocardial FDG uptake patterns and quantitative parameters from routine oncologic PET/CT for cancer therapy-related cardiac dysfunction (CTRCD).
methodsThis retrospective cohort study included lymphoma patients treated with anthracycline-based regimens at a single hospital between 2015 and 2024. Patients underwent FDG PET/CT at baseline and after chemotherapy. CTRCD was operationally defined using the LVEF-based component of the 2022 ESC cardio-oncology guidelines on follow-up echocardiography. Metabolic parameters including maximal standard uptake value (SUVmax), cardiac metabolic volume (CMV), cardiac metabolic activity (CMA), and visual uptake patterns were analyzed on pre and post-treatment PET scans.
resultsPost-treatment SUVmax, CMV, and CMA were significantly higher in patients who developed cardiotoxicity (p = 0.04, 0.017, and 0.03, respectively). In univariable logistic regression, focal/diffuse myocardial uptake was significantly associated with CTRCD, whereas SUVmax ≥8.49 and CMV ≥66.9 showed borderline associations. In multivariable analysis including SUVmax, CMV, and focal/diffuse uptake pattern, only the focal/diffuse uptake pattern remained independently associated with CTRCD (OR = 10.71, 95% CI: 2.10-54.69, p = 0.004). Notably, absent myocardial FDG uptake after treatment was observed only in patients without CTRCD in this cohort. Baseline PET parameters showed no significant predictive value (p = n.s.).
conclusionRoutine post-treatment oncologic FDG PET/CT may provide exploratory information on myocardial metabolic changes associated with CTRCD in lymphoma patients receiving anthracycline-based chemotherapy. Although quantitative PET parameters differed between patients with and without CTRCD, the focal/diffuse myocardial uptake pattern was the only imaging variable that remained independently associated with CTRCD after multivariable adjustment. These findings should be considered hypothesis-generating and require prospective validation using standardized myocardial metabolic preparation and predefined imaging timepoints.
Indexed as
Identifiers
42862278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.